MAXCYTE INC DL-01
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more
MAXCYTE INC DL-01 (MYE0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MAXCYTE INC DL-01 (MYE0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MAXCYTE INC DL-01 - Net Assets Trend (None–None)
This chart illustrates how MAXCYTE INC DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MAXCYTE INC DL-01 (None–None)
The table below shows the annual net assets of MAXCYTE INC DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MAXCYTE INC DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MAXCYTE INC DL-01 Competitors by Market Cap
The table below lists competitors of MAXCYTE INC DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Donga Geologic
KO:028100
|
$67.13 Million |
|
IGB Commercial Real Estate Investment Trust Unit
KLSE:5299
|
$67.15 Million |
|
Sungshin Cemen
KO:004980
|
$67.16 Million |
|
Atinum Investment Co. Ltd
KQ:021080
|
$67.17 Million |
|
Chaintech Technology Corp
TW:2425
|
$67.11 Million |
|
AAEON Technology Inc
TW:6579
|
$67.11 Million |
|
Rubellite Energy Inc
PINK:RUBLF
|
$67.06 Million |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
$67.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MAXCYTE INC DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MAXCYTE INC DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MAXCYTE INC DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MAXCYTE INC DL-01's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MAXCYTE INC DL-01 (MYE0) | €- | N/A | N/A | $67.13 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |